Protection in Simian Immunodeficiency Virus-vaccinated Monkeys Correlates with Anti-HLA Class I Antibody Response

Overview

Journal J Exp Med

Specialties Allergy & Immunology
General Medicine

Date 1992 Oct 1

PMID 1402662

Citations 28

Authors

W L Chan

A Rodgers

R D Hancock

F Taffs

P KITCHIN

G Farrar

F Y Liew

Affiliations

Soon will be listed here.

Abstract

Our earlier reports demonstrated that Cynomolgus macaques vaccinated with either inactivated partially purified simian immunodeficiency virus (SIV), fixed SIV-infected C8166 (a human T lymphoblastoid cell line) cells, or fixed uninfected C8166 cells can be protected against a challenge infection with the 32H isolate of SIVmac 251 (grown in C8166) (Stott, E. J., W. L. Chan, K. H. G. Mills, M. Page, F. Taffs, M. Cranage, P. Greenway, and P. Kitchin. 1990. Lancet. 336:1538; Stott, E. J., P. A. Kitchin, M. Page, B. Flanagan, L. F. Taffs, W. L. Chan, K. H. G. Mills, P. Silvera, and A. Rodgers. 1991. Nature [Lond.]. 353:393). Protection is correlated with the levels of antibody response to cellular antigens in the human cells from which the virus immunogen was grown. However, the mechanism of protection is unclear. We report here the analysis of sera from these protected monkeys and demonstrate that there is positive correlation of protection with antibody response to the HLA class I molecule.

Citing Articles

Exploring HIV Vaccine Progress in the Pre-Clinical and Clinical Setting: From History to Future Prospects.

Kaur A, Vaccari M Viruses. 2024; 16(3).

PMID: 38543734 PMC: 10974975. DOI: 10.3390/v16030368.

A novel multi-component protein vaccine ECP001 containing a protein polypeptide antigen nPstS1 riching in T-cell epitopes showed good immunogenicity and protection in mice.

Yu J, Fan X, Luan X, Wang R, Cao B, Qian C Front Immunol. 2023; 14:1138818.

PMID: 37153610 PMC: 10161251. DOI: 10.3389/fimmu.2023.1138818.

Development of a human leukocyte antigen-based HIV vaccine.

Wang Y F1000Res. 2018; 7.

PMID: 29983917 PMC: 6020720. DOI: 10.12688/f1000research.13759.1.

Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics.

Cantini F, Nannini C, Niccoli L, Petrone L, Ippolito G, Goletti D Mediators Inflamm. 2017; 2017:8909834.

PMID: 28659665 PMC: 5474286. DOI: 10.1155/2017/8909834.

HIV-1 prophylactic vaccines: state of the art.

Lelievre J, Levy Y J Virus Erad. 2016; 2(1):5-11.

PMID: 27482428 PMC: 4946697.

References

McGrath M, Witte O, Pincus T, Weissman I . Retrovirus purification: method that conserves envelope glycoprotein and maximizes infectivity. J Virol. 1978; 25(3):923-7. PMC: 525988. DOI: 10.1128/JVI.25.3.923-927.1978. View

Henderson L, Sowder R, Copeland T, Oroszlan S, Arthur L, Robey W . Direct identification of class II histocompatibility DR proteins in preparations of human T-cell lymphotropic virus type III. J Virol. 1987; 61(2):629-32. PMC: 253995. DOI: 10.1128/JVI.61.2.629-632.1987. View

Osterhaus A, de Vries P, Heeney J . AIDS vaccine developments. Nature. 1992; 355(6362):684-5. DOI: 10.1038/355684b0. View

Maddox J . AIDS research turned upside down. Nature. 1991; 353(6342):297. DOI: 10.1038/353297a0. View

Kitchin P, Almond N, Szotyori Z, Fromholc C, McAlpine L, Silvera P . The use of the polymerase chain reaction for the detection of Simian immunodeficiency virus in experimentally infected macaques. J Virol Methods. 1990; 28(1):85-99. DOI: 10.1016/0166-0934(90)90090-3. View

Murphey-Corb M, Martin L, Montelaro R, Miller M, West M, Ohkawa S . A formalin-inactivated whole SIV vaccine confers protection in macaques. Science. 1989; 246(4935):1293-7. DOI: 10.1126/science.2555923. View

LaThangue N, Shriver K, Dawson C, Chan W . Herpes simplex virus infection causes the accumulation of a heat-shock protein. EMBO J. 1984; 3(2):267-77. PMC: 557334. DOI: 10.1002/j.1460-2075.1984.tb01796.x. View

Hu S, Abrams K, Barber G, Moran P, Zarling J, Langlois A . Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science. 1992; 255(5043):456-9. DOI: 10.1126/science.1531159. View

Langlois A, Weinhold K, Matthews T, Greenberg M, Bolognesi D . The ability of certain SIV vaccines to provoke reactions against normal cells. Science. 1992; 255(5042):292-3. DOI: 10.1126/science.1549775. View

10.

Le Grand R, Vaslin B, Vogt G, Roques P, Humbert M, Dormont D . AIDS vaccine developments. Nature. 1992; 355(6362):684. DOI: 10.1038/355684a0. View

11.

Cranage M, ASHWORTH L, Greenaway P, Murphey-Corb M, Desrosiers R . AIDS vaccine developments. Nature. 1992; 355(6362):685-6. DOI: 10.1038/355685a0. View

12.

Stott E, Chan W, Mills K, Page M, Taffs F, Cranage M . Preliminary report: protection of cynomolgus macaques against simian immunodeficiency virus by fixed infected-cell vaccine. Lancet. 1990; 336(8730):1538-41. DOI: 10.1016/0140-6736(90)93310-l. View

13.

Carlson J, McGraw T, Keddie E, Yee J, Rosenthal A, Langlois A . Vaccine protection of rhesus macaques against simian immunodeficiency virus infection. AIDS Res Hum Retroviruses. 1990; 6(11):1239-46. DOI: 10.1089/aid.1990.6.1239. View

14.

Desrosiers R, Wyand M, Kodama T, Ringler D, Arthur L, Sehgal P . Vaccine protection against simian immunodeficiency virus infection. Proc Natl Acad Sci U S A. 1989; 86(16):6353-7. PMC: 297837. DOI: 10.1073/pnas.86.16.6353. View

15.

Chan W, Lukig M, Liew F . Helper T cells induced by an immunopurified herpes simplex virus type I (HSV-I) 115 kilodalton glycoprotein (gB) protect mice against HSV-I infection. J Exp Med. 1985; 162(4):1304-18. PMC: 2187857. DOI: 10.1084/jem.162.4.1304. View

16.

Putkonen P, Thorstensson R, Ghavamzadeh L, Albert J, Hild K, Biberfeld G . Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys. Nature. 1991; 352(6334):436-8. DOI: 10.1038/352436a0. View